Vertex Pharmaceuticals (VRTX) Accumulated Expenses (2009 - 2026)

Vertex Pharmaceuticals' Accumulated Expenses history runs 18 years deep, the most recent figure standing at $3.0 billion for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 1.1% year-over-year to $3.0 billion; the TTM figure through Mar 2026 stood at $3.0 billion (up 1.1% YoY), while the FY2025 annual figure was $3.0 billion, up 6.55% from the prior year.
• Accumulated Expenses was $3.0 billion for Q1 2026 at Vertex Pharmaceuticals, roughly flat from $3.0 billion in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $3.6 billion in Q3 2025 to a low of $1.7 billion in Q1 2022.
• Historically, Accumulated Expenses has averaged $2.7 billion across 5 years, with a median of $2.8 billion in 2024.
• The sharpest annual moves came in 2022 and 2026: Accumulated Expenses soared 42.96% in 2022, then increased 1.1% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $2.1 billion in 2022, then climbed by 24.86% to $2.7 billion in 2023, then grew by 5.02% to $2.8 billion in 2024, then advanced by 6.55% to $3.0 billion in 2025, then rose by 0.44% to $3.0 billion in 2026.
• The last three Accumulated Expenses figures came in at $3.0 billion (Q1 2026), $3.0 billion (Q4 2025), and $3.6 billion (Q3 2025), per Business Quant data.